The talks on drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of ...

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

The 15 drugs selected for negotiation are prescribed to 5.3 million Medicare beneficiaries to treat conditions ranging from ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

All Medicare Part D plans offer prescription drug coverage through a drug list called a formulary. Since several medications may be in one category or class, each plan decides its own formulary of ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, ...

January is a big time for drugmakers to hike prices. This year saw higher prices for 575 medications so far, including ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

U.S. Health and Human Services Secretary Xavier Becerra says “this is a big deal.” Drug companies oppose the program.